TrialJournal of hematology & oncology2026

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.

Runhui Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.